{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:05:09Z","timestamp":1789110309894,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.cca.2024.119887","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T18:56:31Z","timestamp":1721847391000},"page":"119887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparison of clot waveform analysis with or without adjustment between prothrombin time and activated partial thromboplastin time assays to assess in vitro effects of direct oral anticoagulants"],"prefix":"10.1016","volume":"562","author":[{"given":"Masatoshi","family":"Wakui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusaku","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ziparo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiri","family":"Osada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshino","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumichi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.cca.2024.119887_b0005","first-page":"S48","article-title":"Clot waveform analysis in patients with haemophilia A","volume":"34","author":"Siegemund","year":"2014","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.cca.2024.119887_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-13-1","article-title":"A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis","volume":"13","author":"Lanc\u00e9","year":"2015","journal-title":"Thromb. J."},{"issue":"6","key":"10.1016\/j.cca.2024.119887_b0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ijlh.12724","article-title":"Clot waveform analysis: Where do we stand in 2017?","volume":"39","author":"Sevenet","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"issue":"3","key":"10.1016\/j.cca.2024.119887_b0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jclinpath-2018-205517","article-title":"Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis","volume":"72","author":"Wakui","year":"2019","journal-title":"J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.cca.2024.119887_b0025","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/jclinpath-2019-205922","article-title":"Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays","volume":"72","author":"Wakui","year":"2019","journal-title":"J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.cca.2024.119887_b0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/jclinpath-2020-206835","article-title":"Characterisation of antithrombin-dependent anticoagulants through clot waveform analysis to potentially distinguish them from antithrombin-independent inhibitors targeting activated coagulation factors","volume":"74","author":"Wakui","year":"2021","journal-title":"J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.cca.2024.119887_b0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/ijlh.14120","article-title":"Effects of DOAC-Stop on clot waveform analysis of plasma spiked with antithrombin-dependent and -independent anticoagulants","volume":"45","author":"Ozaki","year":"2023","journal-title":"Int. J. Lab. Hematol."},{"issue":"4","key":"10.1016\/j.cca.2024.119887_b0040","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1055\/s-0038-1657729","article-title":"The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis","volume":"78","author":"Elg","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cca.2024.119887_b0045","doi-asserted-by":"crossref","first-page":"29387","DOI":"10.1038\/srep29387","article-title":"A novel, rapid method to compare the therapeutic windows of oral anticoagulants using the Hill coefficient","volume":"6","author":"Chang","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.cca.2024.119887_b0050","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.thromres.2005.10.013","article-title":"In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I","volume":"118","author":"Terasawa","year":"2006","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.cca.2024.119887_b0055","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.thromres.2011.04.009","article-title":"Recombinant factor VIIa analog NN1731 (V158D\/E296V\/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma","volume":"128","author":"Gray","year":"2011","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.cca.2024.119887_b0060","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1111\/hae.13266","article-title":"Clot waveform analysis using CS-2000i\u2122 distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A","volume":"23","author":"Matsumoto","year":"2017","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.cca.2024.119887_b0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/jth.12455","article-title":"The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis","volume":"12","author":"Hethershaw","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.cca.2024.119887_b0070","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/rth2.12443","article-title":"Effect of anticoagulants on fibrin clot structure: a comparison between vitamin K antagonists and factor Xa inhibitors","volume":"4","author":"Gauer","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.cca.2024.119887_b0075","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-06-0342","article-title":"Expert group on coagulation of the external quality assurance in laboratory medicine in sweden, effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays","volume":"105","author":"Lindahl","year":"2011","journal-title":"Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.cca.2024.119887_b0080","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1111\/jth.12720","article-title":"Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents","volume":"12","author":"Dale","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.cca.2024.119887_b0085","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1160\/TH09-12-0817","article-title":"Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding","volume":"104","author":"Konishi","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.cca.2024.119887_b0090","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/1873-3468.13684","article-title":"Exploring the efficiency of thrombin inhibitors with a quantitative model of the coagulation cascade","volume":"594","author":"Zavyalova","year":"2020","journal-title":"FEBS. Lett."},{"issue":"3","key":"10.1016\/j.cca.2024.119887_b0095","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59\u20137939\u2013an oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.cca.2024.119887_b0100","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14756366.2010.535793","article-title":"Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma","volume":"26","author":"Luettgen","year":"2011","journal-title":"J. Enzyme. Inhib. Med. Chem."},{"issue":"9","key":"10.1016\/j.cca.2024.119887_b0105","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","article-title":"DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles","volume":"6","author":"Furugohri","year":"2008","journal-title":"J. Thromb. Haemost."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124021405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124021405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T12:52:47Z","timestamp":1723553567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124021405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":21,"alternative-id":["S0009898124021405"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.119887","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of clot waveform analysis with or without adjustment between prothrombin time and activated partial thromboplastin time assays to assess in vitro effects of direct oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.119887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119887"}}